Informed Prostate Cancer Patient Support

Prospective study of diagnostic accuracy in the detection of high‐grade prostate cancer in biopsy‐naïve patients with clinical suspicion of prostate cancer who underwent the Select MDx test - Lendínez‐Cano - - The Prostate - Wiley Online Library

Percentage of Gleason pattern 4 and tumor volume predict adverse pathological stage and margin status at radical prostatectomy in grade Group 2 and grade Group 3 prostate cancers - Iakymenko - - The Prostate - Wiley Online Library   Percentage of Gleason pattern 4 and tumor volume predict adverse pathological stage and margin status at radical prostatectomy in grade Group 2 and grade Group 3 prostate cancers Oleksii A. Iakymenko MD , Isabella Lugo MPH , Laurence M. Briski MD , Ivan Nemov MD , Sanoj Punnen MD , Deukwoo Kwon PhD , Alan Pollack MD, PhD , Radka Stoyanova PhD … See all authors First published: 29 June 2021 https://doi.org/10.1002/pros.24183 The data were presented in part at the 108th Annual Meeting of the United States and Canadian Academy of Pathology (USCAP), March 16–21, 2019, National Harbor, Maryland, USA. Abstract

Increasing rates of NCCN high and very high‐risk prostate cancer versus number of prostate biopsy cores - Wenzel - - The Prostate - Wiley Online Library

Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients | bioRxiv

In vitro engineering of a bone metastases model allows for study of the effects of antiandrogen therapies in advanced prostate cancer | Science Advances Abstract While androgen-targeted therapies are routinely used in advanced prostate cancer (PCa), their effect is poorly understood in treating bone metastatic lesions and ultimately results in the development of metastatic castrate resistant prostate cancer (mCRPC). Here, we used an all-human microtissue-engineered model of mineralized metastatic tissue combining human osteoprogenitor cells, 3D printing and prostate cancer cells, to assess the effects of the antiandrogens, bicalutamide, and enzalutamide in this microenvironment. We demonstrate that cancer/bone stroma interactions and antiandrogens drive cancer progression in a mineralized microenvironment. Probing the bone microenvironment with enzalutamide led to stronger cancer cell adaptive responses and osteomimicry than bicalutamide. Enzalutamide presented with better

Black Men Less Likely to Get Best Prostate Cancer Treatments webmd.com Black Men Less Likely to Get Best Prostate Cancer Treatments 3-4 minutes By Robert Preidt HealthDay Reporter TUESDAY, June 29, 2021 (HealthDay News) -- Black American military veterans with aggressive prostate cancer who would benefit from surgery or radiation are less likely to get those treatments than men of other races, despite equal access to health care, a new study finds. "Despite great strides in prostate cancer care over the past few decades, racial disparities in care persist, and there remains a lot to be done to better understand why this is happening and what we can do to finally close the gap," said senior investigator Dr. Danil Makarov, a urologic surgeon at NYU Langone's Perlmutter Cancer Center, in New York City. For the study, the researchers analyzed the medical records of more than 3

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer | NEJM

Bipolar Androgen Therapy Effective in Metastatic Castration-Resistant Prostate Cancer — Cancer ABCs cancerabcs.org Bipolar Androgen Therapy Effective in Metastatic Castration-Resistant Prostate Cancer — Cancer ABCs 3-4 minutes Hormone Therapy (ADT) is the standard of care for prostate cancer. ADT is practiced by either halting the production of androgens or blocking them from interacting with the hormone receptor, so the cancer cells cannot utilize the androgens.   This method of ADT usually results in the development of resistance where the therapy stops working and the cancer continues to progress.    There has been discussion and some recent evaluation of an alternative type of

Metformin Added to Hormone Therapy (ADT) Has Positive Effects on Prostate Cancer — Cancer ABCs In some of our earlier posts, I have suggested that there is evidence that adding an older and inexpensive drug, Metformin, can provide some anticancer effects for men with prostate cancer.   Metformin is an old standby drug commonly used to treat diabetes by controlling glucose blood levels. A recent randomized controlled trial has confirmed that it also has a significant positive effect on men with prostate cancer. The study showed when Metformin is added to the standard of care hormone therapy (ADT) in men with locally advanced and metastatic hormone-sensitive prostate cancer (HSPC or prostate cancer that is still responsive to the ADT) that castrate-resistant prostate cancer-free survival (CRPC-FS) was significantly improved from 20 months to 29 months. The study also indicated that men with locally advanced and low volume of disease derived the most benefit from Metformin. In a

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer | NEJM Abstract Background Metastatic castration-resistant prostate cancer remains fatal despite recent advances. Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic castration-resistant prostate cancer. Lutetium-177 ( 177 Lu)–PSMA-617 is a radioligand therapy that delivers beta-particle radiation to PSMA-expressing cells and the surrounding microenvironment. Methods We conducted an international, open-label, phase 3 trial evaluating 177 Lu-PSMA-617 in patients who had metastatic castration-resistant prostate cancer previously treated with at least one androgen-receptor–pathway inhibitor and one or two taxane regimens and who had PSMA-positive gallium-68 ( 68 Ga)–labeled PSMA-11 positron-emission tomographic–computed tomographic scans. Patients were randomly assigned in a 2:1 ratio to receive either 177 Lu-PSMA-617 (7.4 GBq every 6 weeks for four to six cycles) plus protocol-

Prostate Cancer Drug Improves COVID-19 Survival in Trial medscape.com Prostate Cancer Drug Improves COVID-19 Survival in Trial By Reuters Staff 2 minutes (Reuters) - An experimental prostate cancer drug improved the survival of hospitalized COVID-19 patients in Brazil in a clinical trial, researchers reported on medRxiv ahead of peer review. The drug, proxalutamide being developed by Kintor Pharmaceuticals, blocks the effects of androgen hormones by inactivating their receptors on cell surfaces. Before the spikes on the surface of the coronavirus can break into cells and infect them, they must be "primed" by a protein called TMPRSS2, which is regulated by androgen receptors, explained study co-author John McCoy of Applied Biology Inc in an email to Reuters. In the Brazil trial, 645 hospitalized COVID-19 patients who were breathing on their own received either proxalutamide f

Salvage re-irradiation using stereotactic body radiation therapy for locally recurrent prostate cancer: the impact of castration sensitivity on treatment outcomes | Radiation Oncology | Full Text

Three helpful upcoming webinars | THE "NEW" PROSTATE CANCER INFOLINK prostatecancerinfolink.net Three helpful upcoming webinars 3 minutes Three upcoming webinars deal with (a) the diagnosis and work-up of clinically significant forms of localized prostate cancer; (b) handling anxiety and related issues for men on active surveillance (AS); and (c) whether AS is appropriate for African Americans and others of African ethnicity. See below for details. On Wednesday, June 30, at 7:00 to 8:30 pm Eastern , the Cancer Support Community and Prostate Cancer International will be presenting a webinar on the diagnosis and work-up of men with clinically significant forms of prostate cancer (e.g., Gleason 4 + 3 = 7 or higher or other factors suggesting clinically significant disease). The featured speaker will be Prof. Eric Klein, MD , of the Cleveland Clinic. He will be addressing

Lower salvage radiation dose — are outcomes the same? | THE "NEW" PROSTATE CANCER INFOLINK prostatecancerinfolink.net Lower salvage radiation dose — are outcomes the same? 6-8 minutes A large randomized clinical trial,  SAKK 09/10 , found that a salvage radiation dose of 64 Gy over 32 treatments had equivalent biochemical outcomes compared to 70 Gy over 35 treatments. They treated 350 patients from 2011 to 2014 at 28 hospitals in Germany, Switzerland, and Belgium. The patients were treated with either 3D-CRT (44 percent) or more modern radiation techniques. None had positive lymph nodes. Key patient characteristics were as follows: Biochemically recurrent after prostatectomy (median PSA = 0.3 ng/ml) Positive margins in 45 percent Gleason score ≥ 8 in 18 percent No detectable tumors After 6.2 years of follow-up, outcomes were as follows: Freedom from biochemical progres

Research on AS in management of prostate cancer: your input is important! | THE "NEW" PROSTATE CANCER INFOLINK prostatecancerinfolink.net Research on AS in management of prostate cancer: your input is important! 4 minutes A diverse group of patients, patient advocates, patient spouses/supporters, physicians, and other researchers has come together, with funding support from the Patient Centered Outcomes Research Institute (PCORI), to plan a virtual conference for the fall of 2021. At that conference, we intend to discuss and identify new and evolving opportunities for research into the most appropriate, high-need, high-impact topics affecting the use of active surveillance (AS) for the management of favorable-risk forms of prostate cancer (i.e., low-risk and “favorable” intermediate-risk disease). Our goal is to bring together patient, clinician, and academic input an

When to Stop Cancer Screening: Clinicians' Calculus Varies

Protons Versus Photons for Prostate Cancer: An Answer That Is Long Overdue and Coming - International Journal of Radiation Oncology, Biology, Physics

Photons, Protons, SBRT, Brachytherapy—What Is Leading the Charge for the Management of Prostate Cancer? A Perspective From the GU Editorial Team - International Journal of Radiation Oncology, Biology, Physics

Patient-Reported Quality of Life During Prostate Cancer Radiation Therapy: Insights Into the Patient Experience - International Journal of Radiation Oncology, Biology, Physics : As early detection and treatment advances have optimized control and survival for localized prostate cancer, the emphasis has shifted toward managing the toxicity incurred during treatment. One measure of this toxicity is health-related quality of life (HRQOL), which is now frequently employed as a primary endpoint on large cooperative group prostate cancer clinical trials (eg, NRG RTOG 0938, NRG GU-005, PARTIQoL). Patient-reported outcomes (PROs) are the gold standard for reporting HRQOL because they are less prone to physician bias.

James Michael Tyler: Friends' Gunther reveals cancer diagnosis - BBC News

Extending OS on initial ADT for men with mHSPC | THE "NEW" PROSTATE CANCER INFOLINK

Expert Video Report on castration sensitive and resistant prostate cancer - 2021 ASCO Annual Meeting - YouTube

Biomarkers Pinpoint Resistant Prostate Cancer That May Benefit From Addition of Apalutamide medscape.com Biomarkers Pinpoint Resistant Prostate Cancer That May Benefit From Addition of Apalutamide By Marilynn Larkin 5-6 minutes NEW YORK (Reuters Health) - Biomarkers can be used to identify patients with prostate cancer refractory to first-line androgen deprivation therapy (ADT) who might benefit from the addition of apalutamide to standard treatments, researchers say. "Patients with a high Decipher (genomic test) score clearly benefit the most from the addition of apalutamide to standard treatments," Dr. Felix Feng of the University of California San Francisco told Reuters Health by email. "Moreover," he said, "patients with the basal subtype of prostate cancer should be selected for further intensification of therapy beyond apalutamide, in clinical trials.&quo

AI for Radiation Therapy Works, but Is it Fully Trusted? | MedPage Today medpagetoday.com AI for Radiation Therapy Works, but Is it Fully Trusted? by Mike Bassett, Staff Writer, MedPage Today June 16, 2021 6-7 minutes Radiology > Therapeutic Radiology — Most machine learning-generated plans selected over human plans in head-to-head comparison The use of artificial intelligence in creating radiation treatment plans for prostate cancer appeared to be a success, according to a blinded, head-to-head study. Overall, radiation oncologists considered the vast majority -- 89 of 100 -- of machine learning (ML)-generated plans clinically acceptable for treatment, reported Thomas Purdie, PhD, and colleagues at Prin